We are live on ! Find out more
FT Options

FT Options Portfolio holdings

AUM $66.4M Turnover 60.61%
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+11.45%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$76M
AUM Growth
-$11.1M
Cap. Flow
-$12.3M
Cap. Flow %
-16.15%
Top 10 Hldgs %
38.02%
Holding
408
New
159
Increased
53
Reduced
54
Closed
131
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.3 years

Sector Composition

Rank Sector Weight
1 Healthcare 36.69%
2 Miscellaneous 24.38%
3 Consumer Staples 16.16%
4 Consumer Discretionary 9.31%
5 Communication Services 3.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ABT icon
1
Abbott
ABT
$174B
$7.15M 9.41%
160,970
+13,000
+9% +$562K
2015 Q4
5 quarters
GIS icon
2
General Mills
GIS
$17.4B
$5.1M 6.71%
86,397
+31,920
+59% +$1.95M
2016 Q3
2 quarters
GWPH
3
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.12M 4.11%
+25,829
New +$3.17M
2017 Q1
0 quarters
AKBA icon
4
Akebia Therapeutics
AKBA
$162M
$2.64M 3.47%
286,477
-52,163
-15% -$509K
2015 Q4
5 quarters
K icon
5
DELISTED
Kellanova
K
$2.54M 3.35%
37,301
+31,793
+577% +$2.19M
2016 Q4
1 quarter
FL icon
6
DELISTED
Foot Locker
FL
$2.12M 2.79%
+28,300
New +$2.04M
2017 Q1
0 quarters
MDLZ icon
7
Mondelez International
MDLZ
$80.1B
$1.76M 2.32%
40,904
+27,170
+198% +$1.2M
2016 Q4
1 quarter
POT
8
DELISTED
Potash Corp Of Saskatchewan
POT
$1.71M 2.25%
100,080
+5,000
+5% +$90.6K
2015 Q4
5 quarters
LULU icon
9
lululemon athletica
LULU
$11.2B
$1.38M 1.81%
+26,500
New +$1.74M
2017 Q1
0 quarters
SAGE icon
10
DELISTED
Sage Therapeutics
SAGE
$1.36M 1.8%
19,213
+3,235
+20% +$189K
2016 Q2
3 quarters
UTHR icon
11
United Therapeutics
UTHR
$24.2B
$1.32M 1.73%
9,723
+4,850
+100% +$735K
2016 Q3
2 quarters
KITE
12
CALL
DELISTED
Kite Pharma, Inc.
KITE
$1.29M 1.69%
81,700
+61,700
+309% +$3.82M
2016 Q3
2 quarters
COL
13
DELISTED
Rockwell Collins
COL
$1.26M 1.66%
+13,000
New +$1.22M
2017 Q1
0 quarters
TWX
14
DELISTED
Time Warner Inc
TWX
$1.21M 1.59%
12,385
-5,001
-29% -$484K
2016 Q4
1 quarter
MDCO
15
DELISTED
Medicines Co
MDCO
$1.18M 1.55%
+24,099
New +$1.1M
2017 Q1
0 quarters
DPZ icon
16
Domino's
DPZ
$10.2B
$1.16M 1.53%
6,304
+4,504
+250% +$807K
2016 Q4
1 quarter
BABA icon
17
Alibaba
BABA
$260B
$1.06M 1.4%
9,855
+1,900
+24% +$193K
2016 Q2
3 quarters
OTIC
18
DELISTED
Otonomy, Inc.
OTIC
$1.03M 1.35%
83,747
-34,726
-29% -$506K
2016 Q1
4 quarters
LJPC
19
DELISTED
La Jolla Pharmaceutical Company
LJPC
$989K 1.3%
+33,141
New +$846K
2017 Q1
0 quarters
DIS icon
20
Walt Disney
DIS
$193B
$958K 1.26%
+8,449
New +$930K
2017 Q1
0 quarters
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$242M
$956K 1.26%
119,441
+74,148
+164% +$499K
2015 Q4
5 quarters
TSN icon
22
Tyson Foods
TSN
$19.7B
$913K 1.2%
+14,788
New +$932K
2017 Q1
0 quarters
ESPR icon
23
DELISTED
Esperion Therapeutics
ESPR
$806K 1.06%
22,834
-6,359
-22% -$146K
2016 Q4
1 quarter
APC icon
24
DELISTED
Anadarko Petroleum
APC
$744K 0.98%
+12,000
New +$798K
2017 Q1
0 quarters
BUD icon
25
AB InBev
BUD
$162B
$718K 0.95%
+6,538
New +$703K
2017 Q1
0 quarters

Similar funds

FT Options's Q1 2017 Portfolio in Review

As of Q1 2017, FT Options held 408 positions worth $76M, down 13% from $87.1M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

FT Options withdrew a net $12.3M in Q1 2017, closing 131 positions and reducing 54 holdings. Its most notable exit was JPMorgan Chase, an estimated $3.58M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 46% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, FT Options opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $3.12M.

  • FT Options's largest Q1 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 25,829 shares worth $3.12M.
  • FT Options added most to Kellanova in Q1 2017, an estimated $2.19M increase.
  • FT Options's biggest Q1 2017 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.7M.
  • FT Options fully exited JPMorgan Chase in Q1 2017, selling an estimated $3.58M.
  • FT Options's ten largest holdings make up 38% of its $76M portfolio in Q1 2017.
  • FT Options opened 159 new positions and closed 131 in Q1 2017.
  • FT Options's portfolio value fell 13% quarter-over-quarter to $76M.

Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.